Skip to main content
    R

    Royalty Pharma Plc (RPRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.68
    +0.16 (+0.23%)

    Market Cap: $39.40B

    Last updated: Nov 17, 2026 at 4:40 PM ET

    Royalty Pharma Plc (RPRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Royalty Pharma Plc (RPRX) has a market cap of $39.40B and an enterprise value of $47.48B. It kept 44.80% of revenue as net income over the last 12 months. Its trailing P/E of 13.0x is above its 5-year median of 8.2x.

    Total Valuation

    Enterprise value is 20.49% above the market cap, as debt exceeds cash.

    Market Cap$39.40B
    Enterprise Value$47.48B
    Latest price (Nov 17, 2026)$68.68

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 13, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Last Ex-Dividend DateNov 13, 2026
    Next Payment DateDec 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.22% in the quarter ended Sep 30, 2026 and shrank 0.18% a year over 2 years.

    Shares Outstanding446.03M
    Shares Change (YoY)+3.28%
    Shares Change (QoQ)+0.22%
    Share Count Growth (2Y CAGR)-0.18%

    Valuation Ratios

    Sales and book value multiples are 11.7x and 4.5x. Its year-end P/E ranged from 5.9x to 13.7x from 2020 to 2025.

    P/E Ratio13.0x
    Forward P/E12.6x
    P/S Ratio11.7x
    Forward P/S11.2x
    P/B Ratio4.5x
    P/TBV Ratio5.2x
    P/OCF Ratio13.3x
    PEG Ratio1.2

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 26.1x EBITDA.

    EV / Earnings40.5x
    EV / Sales18.1x
    EV / EBITDA26.1x
    EV / EBIT32.0x

    Price Statistics

    The stock is up 77.08% over 52 weeks and trades 11.55% above its 50-day average.

    Beta (1Y)0.24
    52-Week Change+77.08%
    1-Month Change+14.34%
    3-Month Change+11.64%
    6-Month Change+31.57%
    5-Year Change+69.95%
    Total Return (1Y)+79.50%
    Total Return (3Y CAGR)+40.16%
    Total Return (5Y CAGR)+12.77%
    Return vs SPY (1Y)+64.17%
    Max Drawdown (1Y)-12.12%
    Max Drawdown (3Y)-20.67%
    Sharpe Ratio (1Y)2.57
    Correlation with SPY (1Y)0.15
    50-Day Average$61.57
    200-Day Average$54.60
    52-Week Range$36.68 to $70.13
    RSI (14 Days)67.8
    Average Volume (20 Days)3.43M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.29x current liabilities, and total debt is 1.26x shareholder equity.

    Current Ratio1.29x
    Quick Ratio1.29x
    Debt / Equity1.26x
    Debt / EBITDA5.80x
    Interest Coverage3.98x

    Returns and Efficiency

    Return on invested capital is 7.59% over the last 12 months, against a 5-year average of 7.56%.

    Return on Equity (ROE)17.15%
    Return on Assets (ROA)6.02%
    Return on Invested Capital (ROIC)7.59%
    Return on Capital Employed (ROCE)8.10%
    ROE (5Y Average)18.25%
    ROA (5Y Average)6.58%
    ROIC (5Y Average)7.56%
    Asset Turnover0.13x

    Taxes

    Income tax took 0.00% of pretax income over the last 12 months.

    Income Tax (TTM)$0
    Effective Tax Rate0.00%

    Scores

    RPRX has an Altman Z-Score of 2.49, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score2.49
    Altman Z ZoneGrey
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $2.62B over the last 12 months is up 11.36% from the 12 months before.

    Revenue$2.62B
    Revenue Growth (YoY)+11.36%
    Gross Profit$2.62B
    Operating Income$1.50B
    Pretax Income$1.17B
    Net Income$1.17B
    EBIT$1.48B
    Reported EPS (TTM)$5.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 35.15% of the $19.46B in total assets.

    Cash and Equivalents$513.66M
    Total Debt$8.59B
    Net Debt$8.07B
    Net Debt Per Share$18.10
    Working Capital$346.56M
    Shareholder Equity$6.84B
    Book Value Per Share$15.33
    Tangible Book Value$5.91B
    Tangible Book Per Share$13.26
    Total Assets$19.46B
    Total Liabilities$9.67B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow$2.96B
    FCF Per Share$6.65
    Dividends Paid$893.47M
    Share Repurchases$261.62M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 57.14%, against a 5-year average of 52.45%.

    Gross Margin100.00%
    Operating Margin57.14%
    Pretax Margin44.80%
    Net Margin44.80%
    EBIT Margin56.61%
    Operating Margin (5Y Average)52.45%
    Net Margin (5Y Average)50.23%

    Growth

    Revenue grew 2.06% a year over 3 years, and EPS 9.56% a year.

    Revenue Growth (3Y CAGR)+2.06%
    Revenue Growth (5Y CAGR)+2.30%
    EPS Growth (3Y CAGR)+9.56%
    EPS Growth (5Y CAGR)-2.70%
    FCF Growth (3Y CAGR)+189.30%
    Operating Income Growth (3Y CAGR)+71.89%
    Book Value Per Share Growth (2Y CAGR)+3.33%
    Tangible Book Per Share Growth (2Y CAGR)-4.33%

    Revenue and profit by year

    Dividends and Yields

    RPRX pays out 35.76% of earnings as dividends.

    Dividend Per Share (Annual)$0.94
    Dividend Yield1.37%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+5.01%
    Payout Ratio35.76%
    Earnings Yield7.69%
    Buyback Yield0.85%
    Shareholder Yield3.77%

    Full dividend history

    Peer Position

    Against 6 similar companies, RPRX has the lowest P/E.

    P/E Ratio13.0x vs 31.5x median
    P/S Ratio11.7x vs 16.7x median
    ROIC7.59% vs 4.15% median
    Revenue Growth (Trailing 4 Quarters, YoY)+11.36% vs +18.59% median
    Dividend Yield1.37% vs 0.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 27.62% and EPS growth at 10.51% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+27.62%
    EPS Growth Forecast (2Y CAGR)+10.51%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RPRX

    What is RPRX's market cap?

    Royalty Pharma Plc has a market cap of $39.40B. Its enterprise value, which adds debt and subtracts cash, is $47.48B.

    What is RPRX's P/E ratio?

    Royalty Pharma Plc has a trailing P/E ratio of 13.0x and a forward P/E of 12.6x.

    How many shares of RPRX are outstanding?

    Royalty Pharma Plc has 446.03M shares outstanding. The count is up 3.28% from a year earlier.

    Does RPRX pay a dividend?

    Yes. Royalty Pharma Plc pays $0.94 a share a year, a dividend yield of 1.37%.

    How much debt does RPRX have?

    Royalty Pharma Plc has $8.59B of total debt and $513.66M of cash and equivalents, a net debt position of $8.07B.